Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?
Am J Gastroenterol
.
2022 Mar 1;117(3):501.
doi: 10.14309/ajg.0000000000001567.
Authors
Lynne V McFarland
1
,
Ravina Kullar
2
,
Stuart Johnson
3
,
Jason C Sniffen
4
,
Kristin Woolard
4
,
Ellie J C Goldstein
5
Affiliations
1
University of Washington, Seattle, Washington, USA.
2
Expert Stewardship, Inc., Newport Beach, California, USA.
3
Hines VA Hospital and Loyola University Medical Center, Chicago, Illinois, USA.
4
Infectious Disease Consultants and AdventHealth Orlando, Orlando, Florida, USA.
5
RM Alden Research Laboratory and the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
PMID:
35020606
PMCID:
PMC8893126
DOI:
10.14309/ajg.0000000000001567
No abstract available
Publication types
Letter
Comment
MeSH terms
Clostridioides difficile*
Clostridium Infections* / therapy
Humans
Probiotics* / therapeutic use